Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) R&D In Process (2018 - 2024)

Avalo Therapeutics' R&D In Process history spans 3 years, with the latest figure at $103000.0 for Q2 2024.

  • For Q2 2024, R&D In Process changed N/A year-over-year to $103000.0; the TTM value through Mar 2025 reached $103000.0, down 99.63%, while the annual FY2024 figure was $27.6 million, N/A changed from the prior year.
  • R&D In Process reached $103000.0 in Q2 2024 per AVTX's latest filing, down from $27.5 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $27.5 million in Q1 2024 to a low of $103000.0 in Q2 2024.